Literature DB >> 31042787

Depletion of Myo/Nog Cells in the Lens Mitigates Posterior Capsule Opacification in Rabbits.

Jacquelyn Gerhart1, Liliana Werner2, Nick Mamalis2, Joseph Infanti1, Colleen Withers1, Fathma Abdalla1, Colby Gerhart1, Arturo Bravo-Nuevo1, Olivia Gerhart1, Lori Getts3, Kelly Rhodes3, Jessica Bowers3, Robert Getts3, Mindy George-Weinstein1.   

Abstract

Purpose: Posterior capsule opacification (PCO) is a vision-impairing disease that occurs in some adults and most children after cataract surgery. Contractile myofibroblasts contribute to PCO by producing wrinkles in the lens capsule that scatter light. Myofibroblasts in the lens originate from Myo/Nog cells named for their expression of the MyoD transcription factor and bone morphogenetic protein inhibitor noggin. In this study we tested the effects of depleting Myo/Nog cells on development of PCO.
Methods: Myo/Nog cells were eliminated by injecting the G8 antibody conjugated to 3DNA nanocarriers for the cytotoxin doxorubicin (G8:3DNA:Dox) during cataract surgery in rabbits. The severity of PCO was scored by slit lamp analysis, gross and histologic observation, and immunofluorescence localization of α-smooth muscle actin.
Results: G8:3DNA:Dox specifically induced cell death in Myo/Nog cells in the lens. None of the lenses administered G8:3DNA containing 9 to 36 μM doxorubicin developed greater than trace levels of central PCO and few myofibroblasts were present on the capsule. Less than 9% of these lenses exhibited greater than mild levels of peripheral PCO. Doxorubucin itself reduced PCO; however, myofibroblasts and wrinkles were abundant in the lens, and off-target effects were observed in the ciliary processes and cornea. Conclusions: Myo/Nog cells are the primary source of myofibroblasts in the lens after cataract surgery. Targeted depletion of Myo/Nog cells has potential for preventing PCO and preserving vision.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31042787     DOI: 10.1167/iovs.19-26713

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Mutation of the TRPM3 cation channel underlies progressive cataract development and lens calcification associated with pro-fibrotic and immune cell responses.

Authors:  Yuefang Zhou; Thomas M Bennett; Alan Shiels
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.834

2.  Brain-specific angiogenesis inhibitor 1 is expressed in the Myo/Nog cell lineage.

Authors:  Jacquelyn Gerhart; Jessica Bowers; Lindsay Gugerty; Colby Gerhart; Mark Martin; Fathma Abdalla; Arturo Bravo-Nuevo; Jonathan Tabb Sullivan; Rebecca Rimkunas; Amie Albertus; Lou Casta; Lori Getts; Robert Getts; Mindy George-Weinstein
Journal:  PLoS One       Date:  2020-07-02       Impact factor: 3.240

3.  Tuning Design Parameters of ICAM-1-Targeted 3DNA Nanocarriers to Optimize Pulmonary Targeting Depending on Drug Type.

Authors:  Nikša Roki; Melani Solomon; Jessica Bowers; Lori Getts; Robert C Getts; Silvia Muro
Journal:  Pharmaceutics       Date:  2022-07-19       Impact factor: 6.525

4.  B-Cell-Targeted 3DNA Nanotherapy Against Indoleamine 2,3-Dioxygenase 2 (IDO2) Ameliorates Autoimmune Arthritis in a Preclinical Model.

Authors:  Lauren Mf Merlo; Jessica Bowers; Tony Stefanoni; Robert Getts; Laura Mandik-Nayak
Journal:  Clin Pathol       Date:  2020-08-27

5.  Acute Response and Neuroprotective Role of Myo/Nog Cells Assessed in a Rat Model of Focal Brain Injury.

Authors:  Sahlia Joseph-Pauline; Nathan Morrison; Michael Braccia; Alana Payne; Lindsay Gugerty; Jesse Mostoller; Paul Lecker; E-Jine Tsai; Jessica Kim; Mark Martin; Rushil Brahmbhatt; Grzegorz Gorski; Jacquelyn Gerhart; Mindy George-Weinstein; Jonathan Stone; Sivaraman Purushothuman; Arturo Bravo-Nuevo
Journal:  Front Neurosci       Date:  2021-12-07       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.